Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form
Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...
Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Investor's Business Daily on MSN14h
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.
The New York Times23h
Russia-Ukraine War
A bitter and bloody war in Ukraine has devastated the country, further isolated Russia from the West and fueled economic insecurity around the world. Over 30 officials gathered in Paris for the ...